C4 Therapeutics, Inc.·4

Oct 6, 9:27 PM ET

DOWNEY BRUCE 4

4 · C4 Therapeutics, Inc. · Filed Oct 6, 2020

Insider Transaction Report

Form 4
Period: 2020-10-06
DOWNEY BRUCE
Director
Transactions
  • Conversion

    Common Stock

    2020-10-06+237,148237,148 total
  • Conversion

    Series A Preferred Stock

    2020-10-062,000,0000 total
    Common Stock (237,148 underlying)
  • Conversion

    Common Stock

    2020-10-06+252,394489,542 total
  • Conversion

    Series B Preferred Stock

    2020-10-062,128,5710 total
    Common Stock (252,394 underlying)
Footnotes (1)
  • [F1]Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into the Issuer's Common Stock on a 8.4335-to-one basis upon the closing of the Issuer's initial public offering on October 6, 2020 and had no expiration date.

Documents

1 file
  • 4
    doc4.xmlPrimary

    FORM 4 SUBMISSION